Another key objective is to find vaccines that can provide longer-lasting protection, so people do not need to have a booster shot every ... of the technology in COVID-19 vaccines, the NIAID ...

Novavax on Thursday posted a narrower fourth-quarter loss and said it expects its licensing deal with French drugmaker Sanofi ...

Cornell researchers have developed a new vaccine platform that could provide more robust, longer-lasting protection from both ...

An experimental drug being developed by Sanofi significantly curbed progression of aortic valve stenosis, a common heart ...

Sanofi and Regeneron are throwing an already-approved drug at COVID-19, testing Kevzara (sarilumab) in patients hospitalised with severe disease. The thinking behind this trial is similar to that ...

Novavax Inc. (NVAX) shares climbed over 1% in after-hours trading Thursday as the vaccine maker's revenue outlook and ...

(JTA) — Israel has begun inviting immunocompromised adults to receive a third dose of the COVID-19 vaccine ... a third dose of the vaccine as a booster shot, according to The Times of Israel.

This vaccine is for use as a booster in adults, adolescents and children aged four years and older who have previously received childhood immunisation. Children from four to six years of age ...

Want a battery booster with a built-in air compressor so you can fill up your raft at the lake or a low tire before you head home from the airport? No problem. Would you also like a jump starter ...

After hours: February 28 at 5:44:28 PM EST Loading Chart for SNY ...

Sanofi India Ltd., incorporated in the year 1956, is a Mid Cap company (having a market cap of Rs 11,541.91 Crore) operating in Pharmaceuticals sector. Sanofi India Ltd. key Products/Revenue Segments ...